1. France Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
MedinCell SA

MedinCell SA

26.40
EUR
+0.70
(+2.72%)
815.08MMarket Cap
Dec 09Next Earn
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
0.57
0.59
0.45
0.08
0.14
0.37
0.16
0.39
0.32
0.86
0.59
- -
Basic EPS, GAAP
0.04
-0.25
-0.66
-1.14
-1.19
-0.86
-1
-1.27
-0.86
-0.62
-0.94
- -
Free Cash Flow per Basic Share
-0.08
-0.36
-0.46
-0.97
-0.67
-0.59
-0.94
-0.87
-0.45
0.6
-0.8
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.09
-0.16
-0.81
0.31
-0.72
0.37
-0.53
-1.67
-1.4
-0.49
0.09
0.09
Tangible Book Value per Share
- -
-0.27
-0.95
0.24
-0.79
0.31
-0.6
-1.75
-1.49
-0.58
-0.01
-0.01
Basic Weighted Avg Shares
14
14
14
17
20
22
25
25
29
30
33
33
Sales/Revenue/Turnover
8
9
6
1
3
8
4
10
9
26
20
- -
Operating Margin (%)
5.11
-32.12
-114.62
-1,104.16
-677.59
-190.28
-582.3
-241.8
-228.98
-42.44
-106.44
- -
Depreciation Expense
- -
1
1
1
1
1
2
2
2
2
2
- -
Net Income, GAAP
1
-4
-10
-20
-24
-19
-25
-32
-25
-18
-31
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
7.56
-41.73
-148.66
-1,364.31
-838.53
-231.93
-606.5
-321.9
-273.34
-72.19
-160.27
- -
Working Capital
- -
8
6
18
11
43
-4
-37
11
51
76
76
LT Debt
3
20
29
24
32
40
19
14
53
51
54
54
Total Equity
1
-2
-12
6
-16
9
-13
-42
-41
-16
3
3
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

EUR

•

in mil. unless spec.
Mar'25
Sep'26
Mar'26
ST Debt
7
6
3
LT Borrowings
49
51
52
LT Finance Leases
2
2
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
33
33
36
Market Capitalization
477
794
815

Working Capital

EUR

•

in mil. unless spec.
Mar'25
Sep'26
Mar'26
Total Current Assets
81
61
97
Cash, Cash Equivalents & STI
72
54
85
Accounts Receivable, Net
1
1
2
Inventories
- -
- -
- -
Total Current Liabilities
30
21
21
Payables & Accruals
- -
- -
- -
ST Debt
7
6
3
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-73.75%
-42.46%
-118.72%
Free Cash Flow
8.14%
-90.22%
-249.39%
Net Income, GAAP
-31.59%
16.25%
69.69%
Sales/Revenue/Turnover
42.67%
48.09%
-23.57%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
9
2025
- -
- -
26
2026
- -
- -
20

Semi-annual Earnings Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-0.86
2025
- -
- -
-0.62
2026
- -
- -
-0.94

Semi-annual Dividends Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Christophe Douat
Full Time Employees
150
Sector
Health technology
Industry
Pharmaceuticals: major
Address
3 rue des Frères Lumière Jacou OC France 34830
IPO Date
Oct 8, 2018
Website
medincell.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
MedinCell S.A. (MEDCL.PA) is a clinical-stage biopharmaceutical company that develops long-acting injectable (LAI) therapies using its proprietary BEPO® technology platform, which employs biodegradable polymers and a biocompatible solvent to enable controlled and prolonged release of active pharmaceutical ingredients via subcutaneous or intramuscular injection. The company offers a portfolio of product candidates across therapeutic areas including schizophrenia, post-operative pain, and malaria; key programs include UZEDY® (risperidone LAI, partnered with Teva Pharmaceuticals and launched in the US in 2023 as SteadyTeq™), olanzapine LAI (mdc-TJK, in Phase 3 for schizophrenia with Teva, featuring a favorable safety profile without post-injection delirium/sedation syndrome and NDA submission planned for late 2025), mdc-CWM (celecoxib sustained-release for post-total knee replacement pain, in Phase 3 with Arthritis Innovation Corporation), and additional preclinical and discovery-stage initiatives targeting infectious diseases and other indications. MedinCell collaborates with global pharmaceutical partners and foundations to advance its pipeline, serving patients, physicians, biotech firms, and pharmaceutical companies worldwide with operations focused from its headquarters in Jacou, France. Founded in 2003, the company recently entered a strategic co-development and licensing agreement with AbbVie in April 2024 to develop up to six LAI products across multiple therapeutic areas, receiving a $35 million upfront payment and potential milestones up to $1.9 billion plus royalties; completed a successful €43 million global offering in February 2025 to expand BEPO® into new molecules and indications; reported strong UZEDY® sales growth with raised 2025 revenue outlook to $190-200 million; achieved positive Phase 3 data for olanzapine LAI and mdc-CWM; received a new grant to fight malaria; and established MedinCell Inc. as a US subsidiary.